Regulatory T cells (Treg) are supportive to cancer development in most tissues, but their role in colitisassociated colon cancer (CAC) remains unclear. In this study, we investigated the role of CD4 
Introduction
A particularly striking example of the link between chronic inflammation and cancer is seen in ulcerative colitis, in which chronic colitis or persistent inflammation of the colon is associated with an elevated risk of colorectal cancer (1) . Currently, the pathogenesis of ulcerative colitis is not completely understood, but it is widely accepted that the intestinal pathology is caused by T-cell dysregulation that disturbs the clearance of overreactive and autoreactive cells, in addition to an imbalance of T-cell subsets, including T helper cells (T h ) and regulatory T cells (Treg; refs. 2, 3).
Treg are crucially involved in the maintenance of gut mucosal homeostasis by suppressing abnormal immune responses against commensal flora or dietary antigens. In particular, they exert their function by producing anti-inflammatory cytokines like IL10 and TGFb and by preventing both the activation and the effector function of T cells. Pioneering studies by Powrie and colleagues demonstrated that the pathology in a mouse model of T cell-induced colitis, which mimics human inflammatory bowel disease (IBD), can be prevented by adoptive transfer of Foxp3 þ Treg (4) . The number of Treg is lower in the peripheral blood of patients with active IBD than in that of control subjects (5) . Conversely, the number of Treg is higher in the intestinal mucosa of patients with IBD, and their function is normal, as demonstrated by their ability to suppress the proliferation of effector cells in vitro (6, 7) . The promising results obtained from studies using mouse models of intestinal inflammation suggest that Treg may be an auspicious candidate for IBD therapy. The hope is that increasing the number of Treg in the intestine will offer a replacement for the immunosuppressive drugs that are often ineffective. Nevertheless, although the immunomodulatory effects of Treg may exert a protective or therapeutic effect in intestinal inflammation, the suppression of the immune system can be devastating in cancer immunosurveillance. Indeed, the expression of Foxp3 has been associated with poor prognosis in multiple cancer entities, and Treg have been shown to reduce the host antitumor responses (8, 9) . This concept is established in the case of sporadic cancer, but the role of Treg in immunosurveillance of inflammation-associated cancer remains undefined. Studies have highlighted the presence of lymphocyte infiltration and inflammatory mediators in the tumor microenvironment, a finding indicating that immune cells play an important role in inflammation-mediated tumor promotion. In addition, the numbers of Foxp3 þ Treg are higher in human colon cancers than in surrounding unaffected mucosa (10) . Although some studies of colon cancer have shown a paradoxical and statistically significant association between higher numbers of Treg and a favorable prognosis (11) , the function of Treg in inflammation-related colon cancer is poorly understood.
In the current study, we focused on the role of Treg in tumor progression and tumor rejection in a mouse model of colitisassociated colon cancer. We investigated the phenotype and function of Foxp3 þ Treg in the microenvironment of inflammation-induced colon cancer and determined whether Treg ablation during tumor development is a potential therapeutic strategy.
Materials and Methods

Mice
All animals used in this study were 8-to 12-week-old female and male mice bred and housed under specific pathogen-free conditions in the Laboratory Animal Facility of the University Hospital Essen. BALB/c mice were obtained from Harlan Winkelmann GmbH. C.B6-Tg(Foxp3-DTR/EGFP)23.2Spar (DEREG) mice, C.Foxp3 tm1(cre)Saka (FIC) mice, and C.Il10 tm1Roer (IL-10 FL ) mice were established as described (12) (13) (14) . Crossing FIC mice with IL10 FL mice resulted in mice specifically deficient in IL-10 in Foxp3 þ T cells (termed IL10 fl/fl /FIC mice).
C.Cg-Foxp3 tm2Tch /J (termed Foxp3/eGFP) mice (The Jackson Laboratory), DEREG mice, FIC mice, and IL10
fl/fl /FIC mice were subjected to the azoxymethane/dextran sulfate sodium salt (AOM/DSS) protocol.
Patient samples
Blood samples were obtained from 15 patients with colon cancer (characteristics are summarized in Supplementary  Table S1 ) before therapy was initiated and from 12 healthy volunteers. The study was approved by the Ethics Committee of the Medical Faculty of the University Duisburg Essen (AZ 05-2882). Patients with colon cancer and healthy volunteers participated after giving informed consent.
Isolation of peripheral blood mononuclear cells
Blood samples from patients with colon cancer and healthy donors were collected in NH 4 -Heparin Monovette tubes (SARSTEDT). To isolate peripheral blood mononuclear cells (PBMC), we centrifuged blood with Bicoll density gradient (Biochrom AG). Isolated cells were washed with PBS containing 2 mmol/L EDTA and 2% fetal calf serum (PAA Laboratories) and either analyzed immediately or stored in cell culture medium containing 10% fetal calf serum and 10% DMSO (Carl Roth GmbH) in liquid nitrogen.
AOM/DSS protocol
CAC was induced as previously described (15) . Mice were injected intraperitoneally with the procarcinogen AOM (12.5 mg/kg of body weight; Sigma-Aldrich Isolation of splenocytes, mesenteric lymph node cells, and lamina propria lymphocytes from the colon Spleens were rinsed with an erythrocyte lysis buffer, meshed through a 100-mm cell strainer, and washed with PBS containing 2 mmol/L EDTA and 2% fetal calf serum (FCS). Mesenteric lymph node cells (mLN) were meshed through a 100-mm cell strainer and washed with PBS containing 2 mmol/L EDTA and 2% FCS. Lamina propria lymphocytes (LPL) were isolated as described previously (16) , with minor modifications. Colons were flushed with PBS to remove feces, and opened longitudinally and cut into 1-cm pieces. Tissue pieces were washed twice in PBS containing 3 mmol/L EDTA for 10 minutes at 37 C with rotation. EDTA was removed by washing colon pieces twice in RPMI-1640 containing 1% FCS, 1 mmol/L EGTA, and 1.5 mmol/L MgCl 2 for 15 minutes at 37 C with rotation. Colon pieces were then vortexed intensely, washed with PBS, and digested in RPMI-1640 containing 20% FCS and 100 U/mL collagenase (Sigma-Aldrich) at 37 C for 90 minutes. Remaining tissue was separated from cells by passing the cell suspension through a 40-mm cell strainer and washing with culture medium.
Histology and immunohistochemistry of colon tissues
Tissue sections (4 mm) were prepared from paraffinembedded tissue blocks, stained with hematoxylin and eosin (H&E), and evaluated histopathologically in a blinded manner. The extent of tumor distribution was estimated as 0 to 100%. Expression of Foxp3 protein was detected on paraffinembedded colon sections as described previously (17) .
Antibodies and flow cytometry
Splenocytes, mLNs, and LPLs were stained with fluorochrome-labeled anti-mouse CD4 (RM4-5), CD8 (53-6.7), CD90.1 (OX-7), CD11b (M1/70), CD11c (HL3), F4/80 (BM8, Invitrogen), CD45R/B220 (RA3-6B2), GARP (YGIC86), CD103 (M290), and CD62L (MEL-14). Intracellular detection of Foxp3, CTLA-4 and granzyme B (GzmB) was performed using the Foxp3 Staining Kit from eBioscience with antiFoxp3 (FJK-16s), anti-CTLA-4 (UC10-4F10-11), or anti-GzmB (GB12; Invitrogen), according to the manufacturer's recommendations. All antibodies used in this study, except for GzmB and F4/80, were obtained from either BD Biosciences or eBioscience. For analysis of intracellular IFNg, cells were stimulated for 4 hours with 10 ng/mL PMA and 1 mg/mL ionomycin in the presence of 5 mg/mL Brefeldin A (all Sigma-Aldrich). After staining with anti-CD8 antibodies, cells were fixed with 2% paraformaldehyde, permeabilized with 0.1% NP-40, and stained for intracellular IFNg with anti-mouse IFNg (XMG1.2). Human PBMCs were stained with fluorochrome-labeled anti-human CD4 (RPA-T4), CD8 (RPA-T8), CD25 (BC96), and intracellular Foxp3 (PCH101), according to the manufacturer's instructions (eBioscience). Cells were analyzed by flow cytometry on a LSR II instrument using DIVA software (both from BD Biosciences).
Suppression assay
For murine studies, CD4 Cytokine detection IL10 and IFNg protein were quantified by using the Procarta Cytokine Assay Kit (Panomics) according to the manufacturer's recommendations. The assay was run on a Luminex 200 instrument (Luminex Corporation).
Quantitative RT-PCR
RNA was isolated from sorted cell subsets using the NucleoSpin RNA XS Kit (Macherey-Nagel) according to the manufacturer's instructions. RNA was obtained from colon biopsies using the RNeasy Fibrous Tissue Kit (Qiagen). Following DNase digestion (Qiagen), cDNA was synthesized with M-MLV Reverse Transcriptase (Promega) and Oligo-dT mixed with Random Hexamer primers (Invitrogen). Real-time RT-PCR was performed using the SYBR Green PCR Kit and specific primers for IL10 and RPS9 (Supplementary Table S2 ) on an ABI PRISM cycler (Applied Biosystems, Life Technologies). Relative RNA levels were determined with included standard curves for each individual gene and further normalization to the housekeeping gene RPS9.
Mouse colonoscopy
Numbers and sizes of tumors in the distal part of the colon were determined by microcolonoscopy following a recently described protocol (18) . Tumor development was scored by the total number of tumors and the size of tumors. Tumor grade was determined by size: grade 1, very small but detectable tumor; grade 2, tumor covering up to one-eighth of the colonic circumference; grade 3, tumor covering up to one-fourth of the colonic circumference; grade 4, tumor covering up to half of the colonic circumference; and grade 5, tumor covering more than half of the colonic circumference, as recently described (19) .
Statistical analysis
All results were expressed as mean AE SEM. Differences were assessed by the Student t test or, when means of more than two groups were compared, by 2-way ANOVA followed by Bonferroni multiple comparison test. Kaplan-Meier plots were used to analyze survival. Comparisons of survival curves were made using the log-rank (Mantel-Cox) test. Data analysis was performed with Prism 5.0 software (GraphPad). Statistical significance was set at the level of P < 0.05.
Results
Accumulation of Treg in CAC
To determine whether Treg participate in the development of CAC, we subjected Foxp3/eGFP reporter mice to the AOM/DSS regimen (Fig. 1A) , a well-established protocol for the induction of CAC (15) . The repeated administration of DSS via the drinking water induced a strong inflammatory response in the intestine. Mice lost as much as 10% of their initial body weight during the DSS cycles (Fig. 1B) . At week 12 after AOM/DSS treatment, tumor development was documented by endoscopy (Fig. 1C) . First, we compared the distribution of CD4 þ and CD8 þ T cells in the spleen, mLNs, and the LPLs of colons from healthy mice and CAC mice. We observed a relative reduction of both T cell subsets in the spleens and in the mLNs of CAC mice. Conversely, in tumorbearing colons, the proportion of CD4 þ T cells was signif- (20) (21) (22) . In the spleens and the mLNs, as many as 10% of the CD4 þ T cells expressed GARP, CD103, and CTLA-4, independent of whether the cells were isolated from healthy or diseased mice. In contrast, a significant increase in the expression of GARP, CD103, and CTLA-4 was detectable in the colons of CAC mice, a finding suggesting an activated phenotype of CD4 þ T cells in the colonic tissue of CAC mice ( Fig. 2A and Supplementary Fig.  S1 ). However, the strongest expression of GARP, CTLA-4, and CD103 was detected on CD4 þ Foxp3 þ Treg. In particular, the expression of GARP, CTLA-4, and CD103 on colonic CD4 þ Foxp3 þ Treg was almost twice as high in CAC mice as in healthy mice. More than 40% of the CD4 þ Foxp3 þ Treg in the colons of CAC mice expressed GARP, whereas approximately 80% expressed CD103 and CTLA-4 ( Fig. 2A and Supplementary  Fig. S1 ). To determine whether this activated phenotype was indicative of increased suppressive capacity, we sorted CD4 . Statistical analyses were performed by 2-way ANOVA, followed by the Bonferroni multiple comparison test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. F, tissue sections of representative distal colon samples from healthy and CAC mice at week 12 were fixed and stained with H&E to show pathologic changes. Immunohistochemical staining with Foxp3 antibodies shows Treg (black arrows). Images show magnification at Â100; scale bars, 100 mm.
Increased frequency and suppressive activity of Treg isolated from peripheral blood of patients with colon cancer
To investigate Treg in human colorectal cancer, we analyzed PBMCs from patients with colorectal cancer and healthy volunteers. We found a significantly higher percentage of Foxp3-expressing CD4 þ and CD8 þ T cells in the PBMCs from patients with colorectal cancer as compared with healthy controls (Fig. 3A and Supplementary Fig. S2 ). Because Foxp3 is not an exclusive marker for human Treg, we also assessed CD25 expression by CD4 þ and CD8 þ T cells. Again, the fraction of CD4 þ CD25 hi and CD8 þ CD25 hi T cells was higher in patients with colorectal cancer (Fig. 3B and Supplementary Fig. S2 ). To study patient-and healthy donor-derived Treg at a functional level, we purified CD4 þ CD25 hi cells and cocultured them with autologous CD4 þ CD25 À responder T cells. CD4 þ responder T cells from patients with colorectal cancer exhibited significantly stronger proliferation and IFNg secretion after stimulation (Fig. 3C) . Nevertheless, the suppressive capability of Treg from peripheral blood of patients with colorectal cancer was significantly higher than that of Treg from healthy donors. Moreover, IFNg secretion of CD4 þ responder T cells was decreased when cocultured with Treg from patients with colon cancer (Fig. 3C ). In summary, the frequency and the suppressive activity of Treg from patients with colorectal cancer are enhanced and, therefore, may contribute to tumor progression. First, we evaluated the impact of Treg ablation during the acute inflammation phase. Therefore, DEREG mice were subjected to the AOM/DSS treatment and DT was applied during the DSS cycles from week 1 to week 7 (Fig. 4A) . Importantly, Treg depletion during acute inflammation in AOM/DSS-treated DEREG mice, resulted in significantly reduced survival with severe weight loss (more than 20% of initial body weight) early after DSS treatments (Fig. 4B ). Histologic analysis of the colons confirmed that mice died as a result of intestinal inflammation shown by increased necrosis of the epithelial layer, crypt damage, crypt abscesses and infiltration of leucocytes in the lamina propria of DT-treated DEREG mice (Fig. 4C) , demonstrating that Treg are indispensable for the control of the inflammatory process.
Treg ablation in the late phase of CAC attenuates tumor growth by expanded CD8 þ T-cell effector cells
To ensure the ablation of Treg during the process of tumor formation, we injected DT on a weekly basis starting directly after the last DSS cycle (Fig. 5A) Fig. S4 ). Cytotoxic CD8 þ T cells play a central role in the antitumor immune response, because they can eliminate dysplastic target cells (23, 24) . Remarkably, the ablation of Treg during intestinal tumor formation led to an increase of CD8 þ effector T cells in the colon (Fig. 5C ). Increased frequencies of colonic CD8 þ CD62L low T cells in AOM/DSS/DT-treated mice were accompanied by enhanced cytotoxic activity, as demonstrated by elevated secretion of IFNg and GzmB ( Fig. 5D and Supplementary Fig. S3 ). To assess the impact on tumor progression, we performed histologic analyses and colonic endoscopy. The ablation of Treg led to a significant reduction of tumor distribution in the colons (Fig. 5E) . Furthermore, colonoscopy revealed reduced numbers and tumor sizes in the distal part of the colon when Treg were depleted ( Fig. 5F and G Production of IL10 in the colon is increased in mice with CAC IL10 is particularly important for the function of Treg at environmental interfaces at which tolerance induction is the hallmark of intestinal homeostasis. To assess how activated Treg exert their inhibitory mechanism during CAC, we determined the production of IL10 in biopsy specimens from the colons of healthy mice and CAC mice. IL10 mRNA and IL10 protein was significantly increased in tumor tissues from CAC mice compared with colonic tissues from healthy control mice (Fig. 7A) . Further analysis revealed that the elevated expression of IL10 during CAC depends on CD45 þ lamina propria mononuclear cells. In particular, Treg, macrophages, and dendritic cells expressed higher levels of IL10 (Fig. 7A) .
Deletion of IL10 from Treg is associated with increased tumor progression
To determine whether increased IL10 production of colonic CD4
þ (Fig. 7D) . Furthermore, we detected an increased tumor burden in the distal part of the colons from IL10 fl/fl /FIC mice ( Fig. 7E and F) . Whereas FIC mice developed only a few small tumors (grades 1 and 2), endoscopy revealed enhanced tumor dissemination and larger tumors in the colons of IL10 fl/fl /FIC mice ( Fig. 7F and G). Taken together, these findings indicate that the deletion of IL10 from Treg during inflammation-mediated colon cancer provokes a more severe inflammation, resulting in enhanced tumor formation and growth. 
Discussion
IBD, including ulcerative colitis and Crohn disease, is prototypic chronic inflammatory disease of the gastrointestinal tract, which is associated with an increased risk of colorectal cancer development (1) . The hallmarks of inflammation-related cancer include the presence of inflammatory cells and inflammatory cytokines or chemokines in tumor tissues. However, medical and scientific data from human and mouse studies indicate that it is the balance between proinflammatory and anti-inflammatory activities that strongly influences clinical outcome (25) . In this study, we showed that the induction of CAC augments the frequency of highly activated Treg in colonic tumor tissues. This augmentation may facilitate tumorigenic processes, because transient ablation of Treg dampens tumor progression and results in an improved CD8 þ T-cell response. The clinical relevance is supported by our finding of increased frequencies and suppressive capability of Treg in the peripheral blood of patients with colorectal cancers. þ Treg during the recovery period after the last DSS treatment, we administered DT weekly by intraperitoneal injection. At week 12, total spleen cells, mLNs, and LPLs from the colons of DEREG mice and DEREG mice treated with DT were isolated and stained for the expression of CD4, CD8, CD62L, intracellular IFNg, and GzmB. B, the expression of eGFP (Foxp3) on CD4 þ and CD8 þ T cells was determined by flow cytometry. C, CD8 þ T cells were gated and analyzed for the expression of IFNg, CD62L, and GzmB (D). Bars represent the mean AE SEM of data from at least three independent experiments (with 3-4 mice per group). Statistical analyses were performed by 2-way ANOVA, followed by the Bonferroni multiple comparison test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. E, to determine the distribution of tumors in the distal colon at week 12, we scored histopathology in a blinded fashion. The scatter dot plot comprises the results of three independent experiments (with 3-4 mice per group), and the statistical analysis was performed with the Student t test. Ã , P < 0.05. F, the average number and size of tumors in the distal part of the colon of each mouse was determined by murine endoscopy. Bars represent the mean AE SEM of data from three experiments (with 3-4 mice per group). Statistical analyses were performed by the Student t test. Ã , P < 0.05. G, representative endoscopic images from the distal colon of DEREG mice (I) and DEREG mice treated with DT (II).
Treg are crucially involved in the maintenance of gut mucosal homeostasis by suppressing abnormal immune responses against commensal flora, dietary antigens, or autoantigens (26, 27) . Adoptive transfer of Treg effectively alleviates or prevents symptoms of colitis (28, 29) , and in consequence reduces the incidence of inflammation-induced colon cancer (30) . Interestingly, we detected significantly elevated numbers of Treg within tumors from CAC mice. In various solid tumors, including ovarian and pancreatic cancer, Treg accumulation in tumors and peripheral blood has been generally linked to an unfavorable disease outcome (31, 32) . Conversely, no significant association between the absolute number of tumor-infiltrating Treg and prognosis was established in several studies involving patients with colorectal cancer. Some studies indicate that a high frequency in tumor-infiltrating Treg is associated with a favorable rather than a dismal prognosis. It is hypothesized that Treg suppress bacteria-driven inflammation that promotes carcinogenesis and, thus, benefits the host (33, 34) . However, evidence suggests that Treg may have different effects depending upon the extent of inflammation and tumor development or progression (35) . Here, we demonstrated that the ablation of Treg during acute colitis tremendously exacerbates the inflammatory response, resulting in significant less survival, but depletion of Treg in the late phase of inflammation abrogates the tumor growth accompanied with an increased frequency of CD8 . Statistical analyses were performed by 2-way ANOVA, followed by the Bonferroni multiple comparison test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. D, to determine the distribution and progression of tumors, the average number and size of tumors in the distal part of the colon of each mouse was determined by murine endoscopy at week 12. Bars represent the mean AE SEM of data from one experiment (with 3-4 mice per group). Statistical analyses were performed by the Student t test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001. E, representative endoscopic images from the distal colon of DEREG mice (I), DEREG mice treated with DT (II), DEREG mice treated with aCD8 (III), and DEREG mice treated with DT and aCD8 (IV).
Given the detrimental role of Treg on tumor progression, we attempted to identify target molecules that could bring about selective ablation of these cells. We detected strong expression of GARP, CTLA-4, and CD103 by Treg in the colons of CAC mice. GARP has recently been reported to be a highly specific molecule for activated Foxp3 þ Treg with a strong suppressive function (22, 37) . The frequency of GARP þ Foxp3 þ Treg was found to be highly elevated in advanced hepatocellular carcinoma, and the depletion of GARP þ T cells in combination with other markers restored CD8 þ T cell-dependent GzmB production (38) . This finding is well in line with our results, because Treg isolated from colonic tumors exhibited a higher suppressive capacity than Treg isolated from healthy colons. CTLA-4 is a coinhibitory molecule expressed by activated T cells and by a large proportion of Foxp3 þ Treg. Ipilimumab, an antibody against CTLA-4 molecule was shown to inhibit Treginduced suppression in vivo and has been approved for treatment of metastatic malignant melanoma (39, 40) . Because of the increased expression of GARP and CTLA-4 by Treg in colonic tumors, further exploration of therapeutic ablation of GARP þ T cells and blocking CTLA-4 in CAC is warranted.
In this study, we demonstrated that most tumor-associated Treg in CAC mice express CD103, a cell-surface protein of the integrin family. It has been previously shown that CD103 expression defines a subset of Treg with specific properties: these Treg exhibit enhanced migration into inflamed tissues (41), a finding explaining the accumulation of these cells in the tumors of CAC mice. Another important property of these cells (with 4-5 mice per group). Data were analyzed by 2-way ANOVA, followed by the Bonferroni multiple comparison test. Ã , P < 0.05; ÃÃ , P < 0.01. E and F, the distribution of tumors at week 12 was scored by histopathology in a blinded fashion. The average number and size of tumors in the distal part of the colon of each mouse were determined by endoscopy. Data of two independent experiments (with n ¼ 2-4 mice) are shown and the statistics was determined with the Student t test.
is their improved suppressive function. Tumor-derived CD103
þ Treg suppress CD8 þ T-cell responses more strongly than CD103 À Treg (42, 43) . The observed prevalence of CD103
þ Treg in our model of CAC may explain this enhanced immunosuppression. IL10 is an immunomodulatory cytokine that mainly limits and terminates inflammatory responses. Experimental findings indicate that IL10 may play a role in the pathogenesis of IBD and CAC (44, 45) . Here, we found increased levels of IL10 in colonic tissue of CAC mice. Further, we identified Treg together with macrophages and dendritic cells as the main source of IL10 in the colon. These results imply an IL10-dependent control of the antitumor response. However, we observed that specific inactivation of IL10 in Treg during CAC development led to an increased tumor burden rather than a stronger antitumor response. The reduced activity of IL10-deficient Treg was seemingly compensated for by an increased percentage of Treg in the colons of IL10 In conclusion, we found that Treg play differential roles during CAC. In acute colitis, Treg are indispensable for the control of the inflammatory process and are therefore beneficial to the host. Conversely, during tumor progression, the number of Treg is increased within the tumor, and Treg are strongly involved in the suppression of an effective CD8 þ T cell-mediated antitumor response. Elucidating the balance between the beneficial and the harmful functions of Treg during inflammation-mediated tumor development will facilitate the development of therapeutic options. The reduction of inflammation is the top priority for the treatment of colitis. However, once the inflammation has initiated a tumorigenic process, the specific ablation of Treg may be a promising approach to improving colon cancer therapy.
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